SMC vetoes Sanofi's Jevtana, AZ's Vimovo and Merck's Emend, but OKs Simponi again
08 November 2011
Francesca Bruce
Please Login to read the full article.
08 November 2011
Francesca Bruce
Please Login to read the full article.
RELATED CONTENT
NEWS
- Scots choose chewy Lipitor but refuse Zytiga, Sycrest and Gilenya
- Sanofi's Jevtana still too expensive for NICE, despite end-of-life credentials rethink
- Adverse effects cast doubt over Sanofi's Taxotere follow on Jevtana, says NICE
- Sanofi turns to G-BA for Jevtana benefits decision after vague IQWiG's assessment
ANALYSIS
Other Informa Analysis
COMMENT
Other Informa Comment
EVENTS
07 June 2012
The Rembrandt Hotel, London
12 June 2012
Annecy, France
18 June 2012
Boston Convention & Exhibition Center, Boston, MA
JOB OF THE WEEK
Section Head (m/f)
DRA International/CIS Section
Section Head (m/f)
DRA International/CIS Section
